- Home
- RBOT vs SPRO Comparison
RBOT vs SPRO Comparison
Compare RBOT & SPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- SPRO
- Stock Information
- Founded
- RBOT 2014
- SPRO 2013
- Country
- RBOT United States
- SPRO United States
- Employees
- RBOT N/A
- SPRO N/A
- Industry
- RBOT Medical Specialities
- SPRO Biotechnology: Pharmaceutical Preparations
- Sector
- RBOT Health Care
- SPRO Health Care
- Exchange
- RBOT Nasdaq
- SPRO Nasdaq
- Market Cap
- RBOT 54.2M
- SPRO 45.7M
- IPO Year
- RBOT N/A
- SPRO 2017
- Fundamental
- Price
- RBOT $6.44
- SPRO $0.69
- Analyst Decision
- RBOT Hold
- SPRO Buy
- Analyst Count
- RBOT 2
- SPRO 4
- Target Price
- RBOT $9.25
- SPRO $5.00
- AVG Volume (30 Days)
- RBOT 26.5K
- SPRO 121.5K
- Earning Date
- RBOT 04-28-2025
- SPRO 03-27-2025
- Dividend Yield
- RBOT N/A
- SPRO N/A
- EPS Growth
- RBOT N/A
- SPRO N/A
- EPS
- RBOT N/A
- SPRO N/A
- Revenue
- RBOT N/A
- SPRO $47,977,000.00
- Revenue This Year
- RBOT N/A
- SPRO N/A
- Revenue Next Year
- RBOT N/A
- SPRO N/A
- P/E Ratio
- RBOT N/A
- SPRO N/A
- Revenue Growth
- RBOT N/A
- SPRO N/A
- 52 Week Low
- RBOT $4.27
- SPRO $0.68
- 52 Week High
- RBOT $19.00
- SPRO $1.81
- Technical
- Relative Strength Index (RSI)
- RBOT 30.20
- SPRO 35.60
- Support Level
- RBOT $5.56
- SPRO $0.75
- Resistance Level
- RBOT $8.47
- SPRO $0.80
- Average True Range (ATR)
- RBOT 0.74
- SPRO 0.05
- MACD
- RBOT -0.06
- SPRO -0.01
- Stochastic Oscillator
- RBOT 21.35
- SPRO 5.83
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.